12月15日,长春高新宣布控股子公司长春金赛药业授权其下属全资子公司——上海赛增医疗科技有限公司(“赛增医疗”)作为技术许可方,与被许可方Yarrow Bioscience,Inc.(“Yarrow”)签订GenSci098注射液项目独家许可协议。Yarrow将向赛增医疗支付7000万美元的不可退还、不可抵扣的首付款。近期开发里程碑款项:预计交付相关临床研究报告及数据等资料后向赛增医疗支付5000...
Source Link12月15日,长春高新宣布控股子公司长春金赛药业授权其下属全资子公司——上海赛增医疗科技有限公司(“赛增医疗”)作为技术许可方,与被许可方Yarrow Bioscience,Inc.(“Yarrow”)签订GenSci098注射液项目独家许可协议。Yarrow将向赛增医疗支付7000万美元的不可退还、不可抵扣的首付款。近期开发里程碑款项:预计交付相关临床研究报告及数据等资料后向赛增医疗支付5000...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.